You are here

Tesaro

3 Beaten-Down Biotech Stocks: Can They Recover?

Motley Fool

Sun, 08/12/18 - 01:03 pm

Spark Therapeutics

PARP inhibitors show promise for treating ALS and other brain disorders

Fierce Biotech

Thu, 08/9/18 - 10:04 pm

PARP inhibitors

Tesaro CEO Says Its Drug 'Will Get There' — Analysts Strongly Disagree

Investors.com

Sat, 08/4/18 - 11:51 am

The 3 Worst Biotech Stocks of 2018 (So Far)

Motley Fool

Sun, 07/8/18 - 12:35 pm

Tesaro stock rockets as rumours of Roche takeover abound

Pharmaforum

Fri, 06/22/18 - 10:21 pm

Tesaro Wants a Stronger Grip in Ovarian Cancer

Yahoo/Motley Fool

Tue, 03/27/18 - 10:10 pm

Clovis Oncology

Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer (TSRO)

CP Wire

Mon, 03/26/18 - 02:48 pm

platinum-resistant ovarian cancer

clinical trials vaccines

Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer

Mon, 03/26/18 - 02:41 pm

platinum-resistant ovarian cancer

clinical trials

AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro

Investors Business Daily

Sat, 02/3/18 - 09:09 am

Clovis Oncology

Tesaro's injected chemo nausea med Varubi can cause anaphylaxis, company warns

Fierce Pharma

Mon, 01/15/18 - 06:34 pm

chemotherapy-induced nausea and vomiting

5 Biotech Stocks That Could Be Bought Out in 2018

Yahoo/Motley Fool

Sun, 01/14/18 - 09:38 am

Portola Pharmaceuticals

Esperion Therapeutics

3 Companies Competing to Gain Lead in Ovarian Cancer Market

Yahoo/Zacks.com

Sat, 11/25/17 - 12:35 pm

Clovis Oncology

AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth

Fierce Pharma

Wed, 11/15/17 - 08:51 pm

Clovis Oncology

PARP inhibitors

Tesaro wins FDA OK for an IV version of chemo drug, launches discovery deal with Evotec

Endpoints

Thu, 10/26/17 - 09:34 pm

AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says

Fierce Pharma

Mon, 10/2/17 - 10:10 pm

Clovis Oncology

PARP inhibitors

Ovarian Cancer Market Still Up For Grabs

Barron's

Sat, 08/19/17 - 10:48 am

Clovis Oncology

Watch out Tesaro, AstraZeneca and Merck get FDA OK for broad use of Lynparza

Endpoints

Thu, 08/17/17 - 11:54 pm

Tesaro's Zejula rolls to No. 1 PARP position with big Q2

Fierce Pharma

Wed, 08/16/17 - 10:05 am

PARP inhibitors

Tesaro partners with Takeda in Asia, bagging a $340M deal for Zejula

Endpoints

Thu, 07/27/17 - 09:52 am

Tesaro's rumored buyers aren't biting. Should Gilead go for Incyte instead?

Fierce Pharma

Sat, 07/15/17 - 11:14 am

Gilead Sciences

Pages